Pin the claim to the product
As of September 2026, approved products include semaglutide (Ozempic) and tirzepatide (Mounjaro) for type 2 diabetes, a blood-sugar condition. Semaglutide (Wegovy) and tirzepatide (Zepbound) have approval to help people lose weight and maintain that loss. Each product has its own rules about who can use it.
A compounded preparation is a medicine made to order. Calling it generic or the same as an approved drug can mislead, says the US drug agency, the Food and Drug Administration (FDA).
A National Drug Code is an identifying code in a drug directory. FDA says the code does not establish approval.
Check unfamiliar ingredient names against the offer
BPC-157, ipamorelin and retatrutide are ingredient names you may see in online peptide offers. As of September 26, 2026, FDA records showed no approved US product for any of these three. If one appears in your offer, ask the person treating you to explain why it is being proposed.
Absence from the approval records is not, by itself, a full answer about compounding permission.
For retatrutide, FDA gives a separate answer: federal law does not allow its use in compounding.
Keep generic and compounded separate
In September 2026, the US has no approved generic semaglutide or tirzepatide that can be marketed.
An approved copy of a branded medicine is called a generic. A compounded preparation does not have that approval.